MCID: RTN020
MIFTS: 49

Retinal Vascular Disease

Categories: Cardiovascular diseases, Eye diseases

Aliases & Classifications for Retinal Vascular Disease

MalaCards integrated aliases for Retinal Vascular Disease:

Name: Retinal Vascular Disease 12 15
Retinal Vascular 55 72
Retina Circulation Disorder 12
Retinal Vascular Disorder 72

Classifications:



External Ids:

Disease Ontology 12 DOID:2462
NCIt 50 C35170
SNOMED-CT 68 57534004
UMLS 72 C0154833 C0549652

Summaries for Retinal Vascular Disease

MalaCards based summary : Retinal Vascular Disease, also known as retinal vascular, is related to exudative vitreoretinopathy and retinal vein occlusion, and has symptoms including chest pain An important gene associated with Retinal Vascular Disease is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Blood-Brain Barrier and Immune Cell Transmigration: VCAM-1/CD106 Signaling Pathways and mTOR signaling pathway (KEGG). The drugs Ketorolac and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include endothelial, retina and eye, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Retinal Vascular Disease

Diseases related to Retinal Vascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 368)
# Related Disease Score Top Affiliating Genes
1 exudative vitreoretinopathy 32.4 ZNF408 TSPAN12 NDP LRP5 FZD4
2 retinal vein occlusion 31.3 VEGFA SERPINF1 MTHFR CCL2
3 central retinal vein occlusion 31.2 VEGFA SERPINF1 MTHFR
4 vascular disease 31.2 VEGFA PLG MTHFR INS CCL2 ALB
5 leukostasis 31.1 VEGFA KDR ICAM1
6 macular retinal edema 31.0 VEGFA ICAM1 CCL2
7 background diabetic retinopathy 30.8 VEGFA INS ALB
8 endophthalmitis 30.7 VEGFA PLG ICAM1
9 diabetic neuropathy 30.6 VEGFA INS AKR1B1
10 corneal neovascularization 30.6 VEGFA SERPINF1 PLG KDR
11 diabetic macular edema 30.4 VEGFA SERPINF1 ICAM1 CCL2
12 macular holes 30.4 VEGFA SERPINF1 CCL2
13 atherosclerosis susceptibility 30.4 INS ICAM1 CCL2
14 persistent hyperplastic primary vitreous 30.3 TSPAN12 NDP FZD4
15 retinal disease 30.3 NDP ALB AIPL1
16 macular degeneration, age-related, 1 30.3 VEGFA SERPINF1 PLG PGF KDR CCL2
17 osteoporosis-pseudoglioma syndrome 30.2 NDP LRP5 FZD4
18 norrie disease 30.2 TSPAN12 NDP LRP5 FZD4
19 eclampsia 30.2 PGF MTHFR ALB
20 pre-eclampsia 30.1 VEGFA PGF MTHFR KDR ICAM1
21 microvascular complications of diabetes 5 30.0 VEGFA SERPINF1 PGF KDR INS ICAM1
22 coats disease 30.0 VEGFA TSPAN12 NDP LRP5 KDR FZD4
23 peripheral nervous system disease 29.9 INS ALB AKR1B1
24 retinal vascular occlusion 29.9 VEGFA PLG PGF MTHFR CCL2
25 retinal detachment 29.9 VEGFA TSPAN12 SERPINF1 NDP LRP5 FZD4
26 heart disease 29.9 VEGFA MTHFR INS ICAM1 ALB
27 exudative vitreoretinopathy 1 29.7 ZNF408 VEGFA TSPAN12 NDP LRP5 KDR
28 microvascular complications of diabetes 1 29.7 VEGFA SERPINF1 INS ICAM1 CCN2 CCL2
29 kidney disease 29.3 INS CCN2 CCL2 ALB AKR1B1
30 arteries, anomalies of 29.1 VEGFA PLG PGF INS ICAM1 CCL2
31 genetic central nervous system and retinal vascular disease 12.3
32 rare central nervous system and retinal vascular disease 12.3
33 retinal degeneration 11.6
34 retinitis pigmentosa 10 11.1
35 leukoencephalopathy, brain calcifications, and cysts 11.1
36 hemangioendothelioma 10.8 PLG KDR
37 eales disease 10.7
38 hemifacial spasm 10.7 VEGFA MTHFR
39 diabetic cataract 10.6 VEGFA SERPINF1 AKR1B1
40 angiokeratoma circumscriptum 10.6 VEGFA KDR
41 severe nonproliferative diabetic retinopathy 10.6 VEGFA INS ALB
42 heterophyiasis 10.6 ICAM1 ALB
43 pulmonary artery disease 10.6 PLG MTHFR ALB
44 hepatic vascular disease 10.5 PLG MTHFR ALB
45 leukocoria 10.5 NDP LRP5 FZD4
46 ovarian hyperstimulation syndrome 10.5 VEGFA KDR ALB
47 epithelioid hemangioendothelioma 10.5 VEGFA PGF KDR
48 vitreous disease 10.5 VEGFA PLG CCL2
49 vein disease 10.5 VEGFA PLG MTHFR ALB
50 retinal telangiectasia 10.5 VEGFA TSPAN12 NDP FZD4

Graphical network of the top 20 diseases related to Retinal Vascular Disease:



Diseases related to Retinal Vascular Disease

Symptoms & Phenotypes for Retinal Vascular Disease

UMLS symptoms related to Retinal Vascular Disease:


chest pain

MGI Mouse Phenotypes related to Retinal Vascular Disease:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.27 CCN2 FZD4 ICAM1 INS KDR LRP5
2 homeostasis/metabolism MP:0005376 10.22 AKR1B1 ALB CCN2 FZD4 ICAM1 INS
3 growth/size/body region MP:0005378 10.21 AKR1B1 CCN2 FZD4 ICAM1 INS KDR
4 endocrine/exocrine gland MP:0005379 10.16 ALB CCN2 FZD4 ICAM1 INS LRP5
5 digestive/alimentary MP:0005381 10.13 ALB CCN2 FZD4 ICAM1 INS OCLN
6 immune system MP:0005387 10.07 CCL2 ICAM1 INS KDR LRP5 OCLN
7 integument MP:0010771 9.97 CCN2 FZD4 ICAM1 INS KDR MTHFR
8 nervous system MP:0003631 9.93 AIPL1 FZD4 ICAM1 INS KDR LRP5
9 liver/biliary system MP:0005370 9.86 ALB CCN2 INS KDR LRP5 MTHFR
10 skeleton MP:0005390 9.65 AKR1B1 CCN2 INS KDR LRP5 MTHFR
11 vision/eye MP:0005391 9.5 AIPL1 AKR1B1 CCN2 FZD4 ICAM1 INS

Drugs & Therapeutics for Retinal Vascular Disease

Drugs for Retinal Vascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
2
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
3
Zinc Approved, Investigational Phase 4 7440-66-6 32051
4
Copper Approved, Investigational Phase 4 7440-50-8 27099
5
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
6
Travoprost Approved Phase 4 157283-68-6 5282226
7
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
8
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
9
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
10 Tocotrienol Investigational Phase 4 6829-55-6
11 Anti-Inflammatory Agents Phase 4
12 Anti-Inflammatory Agents, Non-Steroidal Phase 4
13 Mitogens Phase 4
14 Endothelial Growth Factors Phase 4
15 Cyclooxygenase Inhibitors Phase 4
16 Ketorolac Tromethamine Phase 4
17 Micronutrients Phase 4
18 Trace Elements Phase 4
19 Vitamins Phase 4
20 Nutrients Phase 4
21 Tocopherols Phase 4
22 Tocotrienols Phase 4
23 Antioxidants Phase 4
24 Retinol palmitate Phase 4
25 Protective Agents Phase 4
26 retinol Phase 4
27 Vasodilator Agents Phase 4
28
Ranibizumab Approved Phase 3 347396-82-1 459903
29
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
30
Bevacizumab Approved, Investigational Phase 3 216974-75-3
31
Infliximab Approved Phase 3 170277-31-3
32 Hormone Antagonists Phase 3
33 triamcinolone acetonide Phase 3
34 Triamcinolone diacetate Phase 3
35 Triamcinolone hexacetonide Phase 3
36 glucocorticoids Phase 3
37 Hormones Phase 3
38 Immunologic Factors Phase 3
39 Immunosuppressive Agents Phase 3
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
41 Angiogenesis Inhibitors Phase 3
42 Angiogenesis Modulating Agents Phase 3
43 Antineoplastic Agents, Immunological Phase 3
44 Antirheumatic Agents Phase 3
45 Dermatologic Agents Phase 3
46 Gastrointestinal Agents Phase 3
47 Pharmaceutical Solutions Phase 3
48
Regadenoson Approved, Investigational Phase 2 313348-27-5 219024
49
Adenosine Approved, Investigational Phase 2 58-61-7 60961
50
tannic acid Approved Phase 2 1401-55-4

Interventional clinical trials:

(show top 50) (show all 121)
# Name Status NCT ID Phase Drugs
1 Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study Completed NCT02503540 Phase 4 Aflibercept
2 A Randomized, Masked Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery. Completed NCT01542190 Phase 4 Ketorolac Tromethamine
3 Open Label Macugen for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4 pegaptanib sodium (Macugen)
4 Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans. Completed NCT00431691 Phase 4 vitamin and mineral supplement;Escherichia coli Endotoxin (LPS);100% O2;nitroglycerin
5 Influence of Travoprost 0.004% and Latanoprost 0.005% on Retinal Vascular Diameter and Choroidal Blood Flow in Glaucoma Patients Completed NCT00308945 Phase 4 travoprost 0.004% (drug);latanoprost 0.005% (drug)
6 Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: the PLATON Trial Recruiting NCT03405376 Phase 4 Intravitreal aflibercept injection
7 Comparison of Timing and Image Quality of Different Phases of Optos Fluorescein Angiography Between Two Doses of Intravenous Fluorescein: 250mg Versus 500mg Recruiting NCT03244982 Phase 4 Fluorescein Na 10% Inj 500mg;Fluorescein Na 10% Inj 250mg
8 Bevacizumab and Retinal Vascular Occlusions Unknown status NCT00347711 Phase 3 Intravitreal injection
9 Branch Vein Occlusion Study Completed NCT00000162 Phase 3
10 Central Vein Occlusion Study (CVOS) Completed NCT00000131 Phase 3
11 Treatment With Anti-vascular Endothelial Growth Factor in Patients With Branch Retinal Vein Occlusion: 5 Years of Clinical Experience Completed NCT02033031 Phase 3 Lucentis intravitreal injection;Avastin intravitreal injection
12 Intravitreal Bevacizumab and Intravitreal Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA) Completed NCT00997191 Phase 3 Intravitreal triamcinolone;Intravitreal bevacizumab
13 An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy Completed NCT00996437 Phase 2, Phase 3 Ranibizumab;Saline
14 Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination With Laser Photocoagulation for Diabetic Macular Edema Completed NCT00444600 Phase 3 Triamcinolone Acetonide + laser;Ranibizumab + laser;Sham injection + laser;Ranibizumab + deferred laser
15 A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema Completed NCT00105404 Phase 3 Triamcinolone Acetonide
16 A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema Completed NCT00367133 Phase 3 1mg triamcinolone acetonide;4mg triamcinolone acetonide
17 Multicenter Randomized Controlled Trial on the Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease Recruiting NCT03940690 Phase 3 Anti-VEGF injections of bevacizumab
18 Infliximab for Diabetic Macular Edema Refractory to Laser Photocoagulation: a Randomized, Double-Masked, Placebo-Controlled, Cross-Over, 32 Weeks Study Terminated NCT00505947 Phase 3 infliximab;placebo
19 Intravitreal Avastin Versus Intravitreal Avastin and Triamcinolone in Central Retinal Vein Occlusion(CRVO) Unknown status NCT00370630 Phase 2 Avastin (Bevacizumab) and triamcinolone
20 The Effect of A2A Adrenoceptor Stimulation on the Diameter of Retinal Arterioles During Hypoxia in Vivo Unknown status NCT03090087 Phase 2 Regadenoson
21 The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Patients With Diabetic Retinopathy Unknown status NCT03006081 Phase 2 Intravitreal Aflibercept injection
22 Vitamin D Supplementation in Polycystic Ovary Syndrome: a Randomized Controlled Trial. Completed NCT00907153 Phase 1, Phase 2 Placebo
23 Evaluation of the Pain and Visual Outcome Associated With Location of Intravitreal Bevacizumab Injection Completed NCT02790775 Phase 2 Anti-VEGF in quadrant 1;Anti-VEGF in quadrant 2;Anti-VEGF in quadrant 3;Anti-VEGF in quadrant 4
24 Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy (PDR). Completed NCT01281098 Phase 2 Intravitreous injection of pegaptanib
25 Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy (Ranibizumab 0.5 mg Intravitreal Injections) Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy Completed NCT01280929 Phase 2 Intravitreous injection of ranibizumab
26 Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study Completed NCT01096784 Phase 2 rhIGF-I/rhIGFBP-3
27 A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin) Completed NCT00336323 Phase 2 Bevacizumab;Bevacizumab;Bevacizumab;Bevacizumab
28 A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects With Macular Edema Secondary to Vein Occlusions. Completed NCT00407355 Phase 1, Phase 2 Intravitreal injection of ranibizumab .3 dose;Intravitreal injection of Ranibizumab .5 dose
29 Daclizumab for Active, Non-infectious, Sight-threatening Uveitis: A Phase II Pilot Study Completed NCT00070759 Phase 2 Daclizumab
30 A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema Completed NCT00369486 Phase 2 40mg triamcinolone;20mg triamcinolone;40mg triamcinolone + laser;20mg triamcinolone + laser
31 Treatment of Active Anterior Uveitis Associated With JIA, Using Humanized Anti-Tac (HAT, Daclizumab) Completed NCT00130637 Phase 2 Daclizumab
32 Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema Completed NCT00231023 Phase 2 Peribulbar Triamcinolone Acetonide
33 Phase I/II Randomized, Prospective, Double-masked, Sham-controlled Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Central Retinal Vein Occlusion Recruiting NCT03981549 Phase 1, Phase 2
34 Intravitreal Bevacizumab Versus Intravitreal Triamcinolone Acetonide for Refractory Diabetic Macular Edema Unknown status NCT00468351 Phase 1
35 The Safety and Tolerability of Intravitreal Infliximab (Remicade) in Patients With Refractory Diabetic Macular Edema or Choroidal Neovascularization Secondary to Age Related Macular Degeneration- A Pilot Study Unknown status NCT00695682 Phase 1 intravitreal injection of infliximab
36 The Safety and Tolerability of Intravitreal Adalimumab in Patients With Refractory Diabetic Macular Retinopathy or Choroidal Neovascularization or Uveitis: A Pilot Study Unknown status NCT00855608 Phase 1 adalimumab
37 FVF3565s Intravitreal Ranibizumab (rhuFab V2) in the Treatment of Macular Edema Associated With Perfused Central (CRVO) Retinal Venous Occlusive Disease Completed NCT00406796 Phase 1 Ranibizumab
38 Phase I, Open-Label, Single-Center, Randomized, Study of the Safety and Efficacy of 0.5 mg and 2.0 mg Ranibizumab in Patients With Macular Edema Secondary to Perfused Central Retinal Vein Occlusion Completed NCT01028248 Phase 1 Ranibizumab (Lucentis)
39 Pilot Study of Intravitreal Injection of Triamcinolone Acetonide Formulation for Retinal Vascular Disorders Completed NCT00071227 Phase 1 Triamcinolone Acetonide (TAC-PF)
40 An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision Completed NCT02193113 Phase 1 KVD001 Injection
41 Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients Completed NCT02099981 Phase 1 Aminoguanidine
42 Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia Without Neovascularization Completed NCT00457145 Phase 1 Ranibizumab
43 Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia With Neovascularization Completed NCT00457067 Phase 1 Ranibizumab
44 Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia Without Neovascularization (MACTEL 2) Completed NCT00685854 Phase 1 Ranibizumab
45 Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia With Neovascularization (MACTEL 1) Completed NCT00685503 Phase 1 Ranibizumab
46 An Open-Label Phase Ib Study to Evaluate Retinal Imaging After Short-term Use of the Balance Goggles System (BGS) in Patients With Glaucoma Recruiting NCT04035239 Phase 1
47 A Pilot Clinical Trial of the Feasibility and Safety of Intravitreal Autologous Adult Bone Marrow Stem Cells in Treating Eyes With Vision Loss From Retinopathy Enrolling by invitation NCT01736059 Phase 1 CD34+ bone marrow stem cells intravitreal
48 An Open-label, Dose Escalating Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion Terminated NCT00969293 Phase 1 FOV2302 (Ecallantide)
49 Ocular Imaging Study Using Advanced OCT Unknown status NCT02827071
50 Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel. Unknown status NCT00892619

Search NIH Clinical Center for Retinal Vascular Disease

Genetic Tests for Retinal Vascular Disease

Anatomical Context for Retinal Vascular Disease

MalaCards organs/tissues related to Retinal Vascular Disease:

41
Endothelial, Retina, Eye, Bone, Heart, Bone Marrow, Brain

Publications for Retinal Vascular Disease

Articles related to Retinal Vascular Disease:

(show top 50) (show all 4256)
# Title Authors PMID Year
1
Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. 9 38
20232317 2010
2
The effects of oxygen stresses on the development of features of severe retinopathy of prematurity: knowledge from the 50/10 OIR model. 9 38
19639355 2010
3
Non-arteritic anterior ischemic optic neuropathy (NA-AION) after intravitreal injection of bevacizumab (Avastin) for treatment of angoid streaks in pseudoxanthoma elasticum. 9 38
19916212 2009
4
Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy. 9 38
19646547 2009
5
Risk factors and growth factors in ROP. 9 38
19828269 2009
6
Kallidinogenase normalizes retinal vasopermeability in streptozotocin-induced diabetic rats: potential roles of vascular endothelial growth factor and nitric oxide. 9 38
19374851 2009
7
Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy. 9 38
19107135 2009
8
Feedback mechanism between blood vessels and astrocytes in retinal vascular development. 9 38
19577710 2009
9
Association of vitreous inflammatory factors with diabetic macular edema. 9 38
19118698 2009
10
Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. 9 38
18483622 2008
11
VEGF-induced choroidal damage in a murine model of retinal neovascularisation. 9 38
18523088 2008
12
Aquaporin 1 is required for hypoxia-inducible angiogenesis in human retinal vascular endothelial cells. 9 38
18275976 2008
13
Vascular endothelial growth factor C promotes survival of retinal vascular endothelial cells via vascular endothelial growth factor receptor-2. 9 38
16943230 2007
14
Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. 9 38
17420693 2007
15
Molecular targets for retinal vascular diseases. 9 38
17133346 2007
16
Age-dependent retinal capillary pericyte degeneration in galactose-fed dogs. 9 38
17341153 2007
17
Reduction of experimental diabetic vascular leakage by delivery of angiostatin with a recombinant adeno-associated virus vector. 9 38
17293777 2007
18
Retinopathy of prematurity. 9 38
17332988 2007
19
Exogenous leukemia inhibitory factor (LIF) attenuates retinal vascularization reducing cell proliferation not apoptosis. 9 38
16643897 2006
20
Hepatocyte growth factor induces retinal vascular permeability via MAP-kinase and PI-3 kinase without altering retinal hemodynamics. 9 38
16723489 2006
21
Therapeutic potential of angiostatin in diabetic nephropathy. 9 38
16394111 2006
22
Role of the Norrie disease pseudoglioma gene in sprouting angiogenesis during development of the retinal vasculature. 9 38
16123442 2005
23
Predominant rod photoreceptor degeneration in Leber congenital amaurosis. 9 38
16052170 2005
24
Angiopoietin concentrations in diabetic retinopathy. 9 38
15774928 2005
25
Differential expression of connective tissue growth factor in microglia and pericytes in the human diabetic retina. 9 38
15258030 2004
26
VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. 9 38
15303088 2004
27
Pathogenesis of retinopathy of prematurity. 9 38
15135797 2004
28
VEGF and KDR gene expression during human embryonic and fetal eye development. 9 38
14691147 2004
29
An unusual retinal vascular morphology in connection with a novel AIPL1 mutation in Leber's congenital amaurosis. 9 38
12881340 2003
30
Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. 9 38
12652648 2003
31
von Hippel-Lindau disease type 2A in a family with a duplicated 21-base-pair in-frame insertion mutation in the VHL gene. 9 38
12644949 2003
32
Pigment epithelium-derived factor expression in the developing mouse eye. 9 38
12447163 2002
33
Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. 9 38
11596663 2001
34
Role of VEGF-A in endothelial phenotypic shift in human diabetic retinopathy and VEGF-A-induced retinopathy in monkeys. 9 38
11340407 2001
35
Role of vascular endothelial growth factor in diabetic vascular complications. 9 38
10997700 2000
36
[Cell biology of intraocular vascular diseases]. 9 38
10643294 1999
37
VEGF increases retinal vascular ICAM-1 expression in vivo. 9 38
10393052 1999
38
Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. 9 38
10211121 1998
39
Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. 9 38
9287049 1997
40
Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. 9 38
9227268 1997
41
Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. 9 38
9046048 1997
42
Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. 9 38
9008628 1997
43
Vascular endothelial growth factor--its role in retinal vascular proliferation. 9 38
7526213 1994
44
Oxidative stress induces adult T cell leukemia derived factor/thioredoxin in the rat retina. 9 38
8139268 1994
45
Electron microscopic immunocytochemical demonstration of blood-retinal barrier breakdown in human diabetics and its association with aldose reductase in retinal vascular endothelium and retinal pigment epithelium. 9 38
8226103 1993
46
Characterization of galactose-containing glycoconjugates in the human retina: a lectin histochemical study. 9 38
2091899 1990
47
Retinal microvascular features and cognitive change in the Lothian-Birth Cohort 1936. 38
31338413 2019
48
Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease? 38
31193094 2019
49
Adiponectin inhibits high glucose-induced angiogenesis via inhibiting autophagy in RF/6A cells. 38
30982980 2019
50
Topical sustained drug delivery to the retina with a drug-eluting contact lens. 38
31299627 2019

Variations for Retinal Vascular Disease

Expression for Retinal Vascular Disease

Search GEO for disease gene expression data for Retinal Vascular Disease.

Pathways for Retinal Vascular Disease

Pathways related to Retinal Vascular Disease according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.41 VEGFA OCLN KDR ICAM1 CCL2
2
Show member pathways
12.29 LRP5 KDR INS FZD4
3
Show member pathways
12.15 VEGFA KDR ICAM1 CCL2
4
Show member pathways
11.78 PGF KDR ICAM1 CCN2 CCL2
5 11.69 VEGFA ICAM1 CCL2
6
Show member pathways
11.63 VEGFA PGF KDR
7 11.62 VEGFA ICAM1 CCL2
8 11.6 VEGFA KDR ICAM1 CCL2
9
Show member pathways
11.43 PLG MTHFR INS ICAM1 CCL2 ALB
10 11.38 VEGFA KDR INS ALB
11 11.27 VEGFA PLG KDR
12 11.18 PLG ICAM1 CCN2
13
Show member pathways
11.06 VEGFA KDR INS
14 10.74 ICAM1 CCL2

GO Terms for Retinal Vascular Disease

Cellular components related to Retinal Vascular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 VEGFA SERPINF1 PLG PGF NDP KDR
2 collagen-containing extracellular matrix GO:0062023 9.56 SERPINF1 PLG NDP ICAM1
3 extracellular space GO:0005615 9.36 VEGFA SERPINF1 PLG PGF NDP INS
4 platelet alpha granule lumen GO:0031093 9.33 VEGFA PLG ALB

Biological processes related to Retinal Vascular Disease according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.89 VEGFA SERPINF1 KDR CCN2
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.88 KDR ICAM1 CCN2 CCL2
3 Wnt signaling pathway GO:0016055 9.85 TSPAN12 NDP LRP5 FZD4
4 positive regulation of protein phosphorylation GO:0001934 9.81 VEGFA PGF KDR CCN2
5 positive regulation of cell proliferation GO:0008284 9.8 VEGFA PGF LRP5 KDR INS CCN2
6 canonical Wnt signaling pathway GO:0060070 9.74 NDP LRP5 FZD4
7 positive regulation of endothelial cell proliferation GO:0001938 9.73 VEGFA PGF KDR
8 response to hypoxia GO:0001666 9.73 VEGFA PGF MTHFR ICAM1
9 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.71 VEGFA PGF KDR
10 vasculogenesis GO:0001570 9.7 VEGFA KDR FZD4
11 regulation of cell shape GO:0008360 9.67 VEGFA KDR ICAM1 CCL2
12 negative regulation of cell-substrate adhesion GO:0010812 9.62 PLG FZD4
13 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.61 KDR CCL2
14 induction of positive chemotaxis GO:0050930 9.6 VEGFA PGF
15 positive regulation of positive chemotaxis GO:0050927 9.58 VEGFA KDR
16 retinal blood vessel morphogenesis GO:0061304 9.49 LRP5 FZD4
17 retina vasculature morphogenesis in camera-type eye GO:0061299 9.48 NDP FZD4
18 positive regulation of mast cell chemotaxis GO:0060754 9.46 VEGFA PGF
19 response to amino acid GO:0043200 9.43 MTHFR ICAM1 CCN2
20 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.4 VEGFA KDR
21 extracellular matrix-cell signaling GO:0035426 9.16 NDP FZD4
22 vascular endothelial growth factor signaling pathway GO:0038084 9.13 VEGFA PGF KDR
23 angiogenesis GO:0001525 9.1 VEGFA TSPAN12 PGF KDR CCN2 CCL2
24 negative regulation of apoptotic process GO:0043066 10.01 VEGFA KDR ALB AKR1B1 AIPL1

Molecular functions related to Retinal Vascular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.13 VEGFA PGF CCN2
2 Wnt-activated receptor activity GO:0042813 8.8 TSPAN12 LRP5 FZD4
3 protein binding GO:0005515 10.09 ZNF408 VEGFA TSPAN12 SERPINF1 PLG PGF

Sources for Retinal Vascular Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....